A Pan-cancer Landscape of IGF2BPs and Their Association with Prognosis, Stemness and Tumor Immune Microenvironment

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 23

PMID 36686749

Authors

Wei Shao

Hui Zhao

Shoudu Zhang

Qian Ding

Yugang Guo

Kaiqi Hou

Yunchao Kan

Fan Deng

Qian Xu

Affiliations

Soon will be listed here.

Abstract

Background: The human insulin-like growth factor 2 mRNA binding proteins 1-3 (IGF2BP1-3, also called IMP1-3) play essential roles in mRNA regulation, including its splicing, translocation, stability, and translation. However, knowledge regarding the involvement of IGF2BPs in tumor immunity and stemness across cancer types is still lacking.

Methods: In this study, we comprehensively analyzed pan-cancer multi-omic data to determine the correlation of IGF2BPs mRNA and protein expression with various cancer parameters such as mutation frequency, prognostic value, the tumor microenvironment (TME), checkpoint blockade, tumor immune infiltration, stemness and drug sensitivity. Validation of the expression of IGF2BPs in cancer samples and glioma cells were performed by quantitative real-time (qRT)-PCR, and immunofluorescence staining. Investigation of the functional role of IGF2BP3 in glioma stem cells(GSCs) were performed by sphere formation, cytotoxicity, transwell, and wound healing assays.

Results: We found that IGF2BP1 and 3 are either absent or expressed at very low levels in most normal tissues. However, IGF2BP1-3 can be re-expressed in a broad range of cancer types and diverse cancer cell lines, where their expression often correlates with poor prognosis. Immunofluorescence staining and qRT-PCR analyses also showed that the expression of IGF2BP2 and IGF2BP3 were higher in cancer tissues than that in adjacent normal tissues. Moreover, IGF2BPs are associated with TME and stemness in human pan-cancer. Remarkably, IGF2BP3 participated in the maintenance and self-renewal of glioma stem cell (GSCs). Knockdown of IGF2BP3 attenuated GSC and glioma cell proliferation, invasion, and migration.

Conclusions: Our systematic pan-cancer study confirmed the identification of IGF2BPs as therapeutic targets and highlighted the need to study their association with stemness, and the TME, which contribute to the cancer drug-discovery research. Especially, preliminary studies demonstrate the IGF2BP3 as a potential negative regulator of glioma tumorigenesis by modulating stemness.

Citing Articles

A pan-cancer analysis reveals the oncogenic and immunological role of insulin-like growth factor 2 mRNA-binding protein family members.

Zeng F, Chen L, Li J, Yu W, Sa N, Zhang K Discov Oncol. 2025; 16(1):323.

PMID: 40088376 DOI: 10.1007/s12672-025-02077-2.

The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential.

Li D, Hu S, Ye J, Zhai C, Liu J, Wang Z Int J Mol Sci. 2024; 25(22).

PMID: 39596216 PMC: 11595103. DOI: 10.3390/ijms252212150.

The RNA-binding protein IGF2BP1 regulates stability of mRNA transcribed from FOXM1 target genes in hypermitotic meningiomas.

Leclair N, Lucas C, Mirchia K, McCortney K, Horbinski C, Raleigh D Acta Neuropathol. 2024; 148(1):28.

PMID: 39179895 PMC: 11343784. DOI: 10.1007/s00401-024-02788-w.

Systematic analysis of IGF2BP family members in non-small-cell lung cancer.

Gong L, Liu Q, Jia M, Sun X Hum Genomics. 2024; 18(1):63.

PMID: 38867248 PMC: 11167947. DOI: 10.1186/s40246-024-00632-6.

Three Liquid-Liquid Phase Separation-Related Genes Associated with Prognosis in Glioma.

Lv L, Zhang X, Liu Y, Zhu X, Pan R, Huang L Pharmgenomics Pers Med. 2024; 17:171-181.

PMID: 38681062 PMC: 11048218. DOI: 10.2147/PGPM.S442000.

References

Inoue A, Nukiwa T . Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med. 2005; 2(1):e13. PMC: 545205. DOI: 10.1371/journal.pmed.0020013. View

Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q . EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. Mol Cancer. 2022; 21(1):16. PMC: 8759291. DOI: 10.1186/s12943-021-01485-6. View

Xu W, Sheng Y, Guo Y, Huang Z, Huang Y, Wen D . Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. J Cell Physiol. 2019; 234(10):18466-18479. DOI: 10.1002/jcp.28483. View

Qin S, Xia Y, Miao Y, Zhu H, Wu J, Fan L . MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene. Blood Cancer J. 2017; 7(12):651. PMC: 5802429. DOI: 10.1038/s41408-017-0014-y. View

Yang Y, Meng W, Wang Z . Cancer Stem Cells and the Tumor Microenvironment in Gastric Cancer. Front Oncol. 2022; 11:803974. PMC: 8761735. DOI: 10.3389/fonc.2021.803974. View

Fu T, Dai L, Wu S, Xiao Y, Ma D, Jiang Y . Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021; 14(1):98. PMC: 8234625. DOI: 10.1186/s13045-021-01103-4. View

Liu X, He H, Zhang F, Hu X, Bi F, Li K . m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022; 13(5):483. PMC: 9122982. DOI: 10.1038/s41419-022-04950-2. View

Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y . Role of tumor microenvironment in tumorigenesis. J Cancer. 2017; 8(5):761-773. PMC: 5381164. DOI: 10.7150/jca.17648. View

Wang H, Hu X, Huang M, Liu J, Gu Y, Ma L . Mettl3-mediated mRNA mA methylation promotes dendritic cell activation. Nat Commun. 2019; 10(1):1898. PMC: 6478715. DOI: 10.1038/s41467-019-09903-6. View

10.

Gutschner T, Hammerle M, Pazaitis N, Bley N, Fiskin E, Uckelmann H . Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology. 2014; 59(5):1900-11. DOI: 10.1002/hep.26997. View

11.

Kumari S, Kumar S, Muthuswamy S . RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy. J Cancer Res Clin Oncol. 2022; 149(4):1621-1633. DOI: 10.1007/s00432-022-04158-z. View

12.

Samanta S, Sun H, Goel H, Pursell B, Chang C, Khan A . IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG. Oncogene. 2015; 35(9):1111-21. PMC: 5784260. DOI: 10.1038/onc.2015.164. View

13.

Gu C, Shi X, Dai C, Shen F, Rocco G, Chen J . RNA mA Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications. Innovation (Camb). 2021; 1(3):100066. PMC: 8454620. DOI: 10.1016/j.xinn.2020.100066. View

14.

Choi H, Na K . Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: Clinical and prognostic implications. Theranostics. 2018; 8(7):1956-1965. PMC: 5858511. DOI: 10.7150/thno.23767. View

15.

Li B, Zhu L, Lu C, Wang C, Wang H, Jin H . circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021; 12(1):295. PMC: 7804955. DOI: 10.1038/s41467-020-20527-z. View

16.

Oh J, Hwa C, Jang D, Shin S, Lee S, Kim J . Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types. Exp Mol Med. 2022; 54(7):906-921. PMC: 9355997. DOI: 10.1038/s12276-022-00795-z. View

17.

Xu Y, Guo Z, Peng H, Guo L, Wang P . IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma. J Cell Mol Med. 2021; 26(2):410-421. PMC: 8743660. DOI: 10.1111/jcmm.17093. View

18.

Wang T, Kong S, Tao M, Ju S . The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 2020; 19(1):88. PMC: 7216508. DOI: 10.1186/s12943-020-01204-7. View

19.

Mukhopadhyay P, Farrell T, Sharma G, McGuire T, OKane B, Sharp J . Heterogeneity of functional properties of Clone 66 murine breast cancer cells expressing various stem cell phenotypes. PLoS One. 2013; 8(11):e78725. PMC: 3827106. DOI: 10.1371/journal.pone.0078725. View

20.

Zhang Z, Zhang C, Luo Y, Zhang G, Wu P, Sun N . RNA N -methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential. Clin Transl Med. 2021; 11(9):e525. PMC: 8473646. DOI: 10.1002/ctm2.525. View